Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PTLA $29.35 4.0700 +16.10%
CERU $4.53 0.3100 +7.35%
PARD $0.16 0.0100 +6.67%
GLYC $7.34 0.4000 +5.76%
BCRX $10.29 0.5100 +5.21%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $19.00 -1.9900 -9.48%
CNDO $1.92 -0.1800 -8.57%
CVM $0.84 -0.0717 -7.86%
CRIS $1.31 -0.1000 -7.09%
SNSS $6.64 -0.5050 -7.07%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

FDA Recommendation Doesn't Apply to Androxal, Repros Says

(Wall Street Journal) Sept 22, 2014 - Repros Therapeutics said a Food and Drug Administration advisory panel recommendation doesn't directly apply to its lead drug candidate to treat low testosterone caused by secondary hypogonadism.
read article (paid subscription required) 



Regeneron Says Allergy Drug May be Darling of its Pipeline

(Reuters) Sept 19, 2014 - Regeneron Pharmaceuticals Inc has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.
read article 



Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit

(TheStreet) Sept 19, 2014 - Activist investor Alex Denner is gaining an ally on Ariad's Board.
read article 



The West Clinic Earns National Recognition For Quality Care

(Yahoo! Finance) Sept 22, 2014 - The West Clinic of Memphis, TN announced today that it has received the National Committee for Quality Assurance (NCQA) Recognition as a Patient-Centered Specialty Practice (PCSP) for its responsiveness to patients and medical colleagues, cooperation and integration with other health care groups, and dedication to continuous improvement.
read article 



Guest Article: Endpoints for Studies of Ovarian Cancer

(MedPage Today) Sept 21, 2014 - Two gynecologic oncologists discuss the challenges involved in choosing appropriate clinical endpoints to evaluate treatment for ovarian cancer.
read article (free registration required) 



Op-Ed: A Cancer Battle We Can Win

(New York Times) Sept 21, 2014 - CT screening for lung cancer can save thousands of lives each year.
read article 



ASCO Statement on FDA’s Framework Guidance on Laboratory-Developed Tests

(ASCO) Sept 19, 2014 - ASCO supports the U.S. Food and Drug Administration's Framework Guidance that proposes a risk-based approach to regulation of laboratory-developed tests, particularly genomic tests that, increasingly, are being used to guide therapy selection for patients with cancer.
read press release 



New International Guidelines for Advanced Breast Cancer Released

(Medscape Medical News) Sept 22, 2014 - The latest international consensus guidelines for the management of advanced breast cancer were published online September 18 in the Annals of Oncology and September 20 in the Breast.
read article (free registration required) 



Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma

(CNN Money) Sept 22, 2014 - Progenics Pharmaceuticals, Inc. today presented positive data from a pivotal phase 2 clinical study of Azedra(TM) in an oral presentation at the International Symposium of Pheochromocytoma and Paraganglioma (ISP) in Kyoto, Japan.
read article 



Singapore Researchers Discover a Gene that Increases Incidence of AML

(Science Codex) Sept 22, 2014 - A novel study by the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) found that an increase in a gene known as Leo1 affects other genes that are directly implicated in acute myelogenous leukaemia (AML), increasing the incidence of cancer.
read article 



Melanoma Risk Found to Have Genetic Determinant

(Dartmouth-Hitchcock/Norris CCC) Sept 18, 2014 - A leading Dartmouth researcher co-authored a paper published in the Journal of the National Cancer Institute that proves longer telomeres increase the risk of melanoma.
read press release 



Good Bowel Cleansing Is Key for High-Quality Colonoscopy

(AGA) Sept 22, 2014 - U.S. multi-society task force releases consensus statement on adequate bowel cleansing for colonoscopy.
read press release 



Clinical Trial Begins in Boston for MRI-Compatible Robot

(Worcester Polytechnic Institute [Worcester, MA]) Sept 18, 2014 - Developed by researchers at WPI, Johns Hopkins, and Brigham and Women's Hospital, the robotic system, designed to improve prostate cancer biopsies, is being tested as part of a larger clinical trial at BWH.
read press release 



Almost Half of Cancer Patients Diagnosed Too Late

(The Guardian UK) Sept 21, 2014 - Almost half of people who get cancer are diagnosed late, which makes treatment less likely to succeed and reduces their chances of survival, Cancer Research UK warns on Monday.
read article 



'Avatar' Mice Help Develop New Cancer Treatments

(Boston Globe) Sept 22, 2014 - Beth Israel Deaconess has started experimenting with the avatar approach for a handful of patients with cancers of the prostate, pancreas, breast, and adrenal gland.
read article (free registration required) 



Study of Smoking Cancer Patients Fuels E-cigarette Debate

(Reuters) Sept 22, 2014 - The fierce debate over whether e-cigarettes can help people quit smoking took another twist on Monday as a research paper on their use by cancer patients was criticized as flawed.
read article 



Amgen Files 'Breakthrough' Leukaemia Drug in the US

(PharmaTimes UK) Sept 22, 2014 - Biotechnology giant Amgen has filed its investigational cancer immunotherapy blinatumomab in the US for the treatment of certain forms of acute lymphoblastic leukaemia (ALL).
read article 



Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis

(Threshold) Sept 22, 2014 - Threshold Pharmaceuticals, Inc. today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS).
read corporate press release 



Gynecologists Resist FDA Over Popular Surgical Tool

(Wall Street Journal) Sept 21, 2014 - Doctors nationwide are still using a gynecological tool months after the U.S. Food and Drug Administration warned that it can spread undetected cancer, demonstrating the limits of the regulator's reach into clinical practice.
read article (paid subscription required) 



China Fines GlaxoSmithKline Nearly $500 Million For Bribery

(CNNMoney) Sept 19, 2014 - Drug giant GlaxoSmithKline has apologized to China for bribing health care workers and will pay a fine of nearly half a billion U.S. dollars.
read article 



GlaxoSmithKline to End Promotional Pay to Doctors

(Boston Globe) Sept 19, 2014 - The research chief of GlaxoSmithKline PLC said Wednesday that the British drug giant is becoming a more “open” organization, moving toward greater collaboration in developing medicines and building confidence with the public by halting payments to doctors for giving promotional talks about the company’s products.
read article (free registration required) 



Lilly's Type 2 Diabetes Drug Trulicity Gets FDA OK

(Morningstar/Dow Jones Newswires) Sept 18, 2014 - Eli Lilly & Co.'s Type 2 diabetes drug Trulicity has been approved by the U.S. Food and Drug Administration, the agency said Thursday.
read article 



Legislation Would Prevent Drug Makers From Thwarting Generic Rivals

(Wall Street Journal/Pharmalot blog) Sept 19, 2014 - A bill has been introduced in Congress that would end a practice that generic drug makers say is used by their brand-name rivals to thwart competition.
read article (paid subscription required) 



Medicare Advantage Reports Growth Despite Cuts

(The Hill) Sept 18, 2014 - Enrollment in private Medicare plans appears to be rising steadily despite substantial cuts to the program under ObamaCare.
read article 



Memorial Sloan Kettering Celebrates Ground Breaking For New Monmouth County Cancer Center

(NJ.com) Sept 19, 2014 - On Thursday afternoon, a few dozen people gathered in the lobby of the vacant former Lucent Technologies building to celebrate the ceremonial ground breaking for a new tenant.
read article